Clofazimine

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 96-99

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; CYCLOSERINE; DAPSONE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN;

ABDOMINAL PAIN; ABORTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRY SKIN; ENCAPSULATION; EPIGASTRIC PAIN; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FECES; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL TOXICITY; GENOTOXICITY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; ICHTHYOSIS; LEPROSY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN PRURITUS; SPUTUM; STILLBIRTH; SUICIDE; SWEAT DISCOLORATION; TASTE DISORDER; TERATOGENICITY; TUBERCULOSIS; URINE; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249131663     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70006-4     Document Type: Review

References (24)

1. Reddy V., et al. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 40 (1996) 633-636
2. Fortun J., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56 (2005) 180-185
3. Oliva B., et al. Anti-staphylococcal activity and MOA of clofazamine. J Antimicrob Chemother 53 (2004) 435-440
4. Steele H., et al. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother 44 (1999) 209-216
5. Cholo M., et al. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J Antimicrob Chemother 57 (2006) 79-84
6. van Rensburg C., et al. Antimicrobial activities of clofazamine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 36 (1992) 2729-2735
7. Barry V., et al. A new series of phenazines (riminocompounds) with high antituberculosis activity. Nature London 179 (1957) 1013-1015
8. Reddy V., et al. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 43 (1999) 615-623
9. Boshoff H., et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 279 (2004) 40174-40184
10. Rastogi N., et al. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33 (1996) 167-175
11. De Logu A., et al. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49 (2002) 275-282
12. Bulatovic V., et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 46 (2002) 2765-2771
13. Adams L., et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 43 (1999) 1638-1643
14. Mehta R. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium M. intracellulare complex infection. Antimicrob Agents Chemother 40 (1996) 1893-1902
15. Peters K., et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 45 (2000) 77-83
16. Gangadharam P., and Reddy M. Carryover of clofazimine into culture media. Antimicrob Agents Chemother 39 (1995) 1388-1389
17. Mukherjee J., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363 (2004) 474-481
18. du Toit L., et al. Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 7 (2006) 118
19. Sansarricq H (editor, 2004). Multidrug therapy against leprosy: development and implementation over the past 25 years. Geneva: WHO. ISBN 92 4 159176 5.
20. Nix D., et al. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis 84 (2004) 365-373
21. Mamidi N., et al. Tissue distribution and deposition of clofazimine in rat following subchronic treatment with or without rifampicin. Arzneimittelforschung 45 (1995) 1029-1031
22. Peters K., et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 45 (2000) 77-83
23. Das R., and Roy B. Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice in vivo. I. Chromosome analysis in bone marrow and spermatocytes. Mutat Res 241 (1990) 161-168
24. Roy B., and Das R. Evaluation of genotoxicity of clofazimine, an antileprosy drug, in mice in vivo. II. Micronucleus test in bone marrow and hepatocytes. Mutat Res 241 (1990) 169-173